Based on the TLRY stock forecast from 8 analysts, the average analyst target price for Tilray Inc. is CAD 12.59 over the next 12 months. TLRY stock forecast average analyst rating is Buy. Stock Target Advisor’s own stock analysis of Tilray Inc. is Slightly Bullish, which is based on 7 positive signals and 5 negative signals. At the last closing, Tilray Inc.’s stock price was CAD 5.08. Tilray Inc.’s stock price has changed by +0.91% over the past week, +0.88% over the past month and -72.30% over the last year.
Research, cultivation, manufacture, marketing, and distribution of medical cannabis products are all activities carried out by Tilray Brands Inc. Cannabis business, distribution business, beverage alcohol business, wellness business, and development business make up its five operating segments. Previously, the business was known as Tilray, Inc. The corporate headquarters of Tilray Brands Inc. are in New York, New York, and it was established in 2018.
What we like:
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The stock’s annual returns have been stable and consistent compared to its sector peers (for a hold period of at least 12 months) and are in the top quartile. Although stability is good, also keep in mind it can limit returns.
Underpriced compared to book value
The stock is trading low compared to its peers on a price-to-book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Superior return on equity
The company management has delivered a better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior return on assets
The company management has delivered a better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior Revenue Growth
This stock has shown top quartile revenue growth compared to its sector in the previous 5 years.
What we don’t like:
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns, the returns are unpredictable. Proceed with caution.
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Negative cash flow
The company had negative total cash flow in the most recent four quarters.
Overpriced on a free cash flow basis
The stock is trading high compared to its peers on a price-to-free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering buying.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector.